, Volume 66, Issue 14, pp 1817–1829 | Cite as

Combination Therapy in Epilepsy

When and What to Use
Therapy In Practice


After being regarded as a last resort for over two decades, the role of combination therapy as a treatment strategy for epilepsy is undergoing re-evaluation. This is a result of the growing appreciation that all seizures cannot be controlled by monotherapy in a substantial proportion of patients, and of the development of a range of modern antiepileptic drugs (AEDs), some of which are better tolerated and less prone to complex pharmacokinetic drug interactions than their older counterparts.

Robust evidence to guide clinicians on when and how to combine AEDs is lacking, and current practice recommendations are largely empirical. Monotherapy should remain the treatment of choice for newly diagnosed epilepsy. A combination of two AEDs can be considered after failure, resulting from lack of efficacy, of one or two different monotherapy regimens. A few patients will become seizure-free with a combination of three AEDs, but treatment with a combination of four or more is unlikely to be successful. There is some evidence to support a pharmacomechanistic approach to AED combination. Care should be taken to avoid excessive drug load, which is associated with increased toxicity.

Bigger and better randomised, controlled studies are needed to determine the optimal time and way to combine AEDs.


Carbamazepine Valproic Acid Lamotrigine Topiramate Pregabalin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Professor Brodie has received research grants and/or honoraria from and/or acted as a consultant at some time for the following pharmaceutical companies: Sanofi-Aventis, Glaxo SmithKline, Pfizer, Janssen-Cilag, Eisai, UCB, Novartis and Cephalon. Dr Kwan has received research grants and/or honoraria at some time from the following pharmaceutical companies: Pfizer, Janssen-Cilag and UCB.


  1. 1.
    Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: 1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Reynolds EH, Chadwick D, Galbraith AW. One drug (phenytoin) in the treatment of epilepsy. Lancet 1976; 307: 923–6CrossRefGoogle Scholar
  3. 3.
    Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. BMJ 1979; 2: 1023–5PubMedCrossRefGoogle Scholar
  4. 4.
    Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983; 24: 368–76PubMedCrossRefGoogle Scholar
  5. 5.
    Albright P, Bruni J. Reduction of polypharmacy in epileptic patients. Arch Neurol 1985; 42: 797–9PubMedCrossRefGoogle Scholar
  6. 6.
    Deckers C. Overtreatment in adults with epilepsy. Epilepsy Res 2002; 52: 43–52PubMedCrossRefGoogle Scholar
  7. 7.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9PubMedCrossRefGoogle Scholar
  8. 8.
    Mohanraj R, Brodie MJ. Outcomes in newly diagnosed localisation-related epilepsies. Seizure 2005; 14: 318–23PubMedCrossRefGoogle Scholar
  9. 9.
    Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006; 13: 277–82PubMedCrossRefGoogle Scholar
  10. 10.
    Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60 Suppl. 4: 2–12CrossRefGoogle Scholar
  11. 11.
    Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001; 90: 21–34PubMedCrossRefGoogle Scholar
  12. 12.
    Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553–64PubMedCrossRefGoogle Scholar
  13. 13.
    Mawer CE, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995; 68: 209–31PubMedCrossRefGoogle Scholar
  14. 14.
    Deckers CLP, Hekster YA, Keyser A, et al. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997; 38: 570–5PubMedCrossRefGoogle Scholar
  15. 15.
    Deckers CLP, Hekster YA, Keyser A, et al. Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 1997; 62: 592–5PubMedCrossRefGoogle Scholar
  16. 16.
    WHO Collaborating Centre for Drug Statistics Methodology. ATC / DDD Index 2006 [online]. Available from URL: [Accessed 2005 Dec 28]
  17. 17.
    Lammers MW, Hekster YA, Keyser A, et al. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Epilepsia 1995; 36: 440–6PubMedCrossRefGoogle Scholar
  18. 18.
    Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985–91PubMedCrossRefGoogle Scholar
  19. 19.
    Cunnington M, Tennis P, for the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955–60PubMedCrossRefGoogle Scholar
  20. 20.
    Morrow JI, Russell A, Gutherie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–8PubMedCrossRefGoogle Scholar
  21. 21.
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347–56PubMedCrossRefGoogle Scholar
  22. 22.
    Radulov LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 1995; 35: 155–61CrossRefGoogle Scholar
  23. 23.
    Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407–13PubMedCrossRefGoogle Scholar
  24. 24.
    Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707–24PubMedCrossRefGoogle Scholar
  25. 25.
    May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023–42PubMedCrossRefGoogle Scholar
  26. 26.
    Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763–80PubMedCrossRefGoogle Scholar
  27. 27.
    PROGRESS Collaborative Group. Randomised trial of perinopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41CrossRefGoogle Scholar
  28. 28.
    Czuczwar SJ, Borowicz KK. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002; 52: 15–23PubMedCrossRefGoogle Scholar
  29. 29.
    Temkin MR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: metanalysis of controlled trials. Epilepsia 2001; 42: 515–24PubMedCrossRefGoogle Scholar
  30. 30.
    Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004; 9: 110–9PubMedGoogle Scholar
  31. 31.
    Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005; 19: 897–908PubMedCrossRefGoogle Scholar
  32. 32.
    Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42: 1387–94PubMedCrossRefGoogle Scholar
  33. 33.
    Baldy-Moulinier M, Covanis A, et al. Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. Seizure 1998; 7: 513–20PubMedCrossRefGoogle Scholar
  34. 34.
    Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005; 7 Suppl. 1: S1–64PubMedCrossRefGoogle Scholar
  35. 35.
    Deckers CLP. Place of polytherapy in the early treatment of epilepsy. CNS Drugs 2002; 16: 155–63PubMedCrossRefGoogle Scholar
  36. 36.
    Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9: 464–8PubMedCrossRefGoogle Scholar
  37. 37.
    Beghi E, Gatti G, Tonini C, et al. Adjuctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57: 1–13PubMedCrossRefGoogle Scholar
  38. 38.
    Lindberger M, Alenius M, Frisen L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. Epilepsia 2000; 41: 1289–95PubMedCrossRefGoogle Scholar
  39. 39.
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859–80PubMedCrossRefGoogle Scholar
  40. 40.
    Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001; 46: 259–70PubMedCrossRefGoogle Scholar
  41. 41.
    Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590–600PubMedCrossRefGoogle Scholar
  42. 42.
    Brodie MJ, Yuen AWC. Lamotrigine substitution study: synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423–32PubMedCrossRefGoogle Scholar
  43. 43.
    Pisani F, Otero G, Russo MF, et al. The efficacy of valproate-lamotrigine comedicatoin in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–6PubMedCrossRefGoogle Scholar
  44. 44.
    Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797–802PubMedCrossRefGoogle Scholar
  45. 45.
    Cereghino JJ, Brock JT, Van-Meter JC, et al. The efficacy of carbamazepine combination in epilepsy. Clin Pharmacol Ther 1975; 18: 733–41PubMedGoogle Scholar
  46. 46.
    Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study Group. Epilepsy Res 1999; 34: 199–205CrossRefGoogle Scholar
  47. 47.
    Leach JP, Brodie MJ. Synergism with GABA-ergic drugs in refractory epilepsy. Lancet 1994; 343: 1650PubMedCrossRefGoogle Scholar
  48. 48.
    Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351: 958–9PubMedGoogle Scholar
  49. 49.
    Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364–74PubMedCrossRefGoogle Scholar
  50. 50.
    Kwan P, Brodie MJ. Pharmacological treatment of epilepsy in adolescents and adults. In: Gilman S, editor. MedLink Neurology [online]. Available from URL: [Accessed 2006 Sep 5]
  51. 51.
    Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002; 11: 349–51PubMedCrossRefGoogle Scholar
  52. 52.
    Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183–7PubMedCrossRefGoogle Scholar
  53. 53.
    Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597–607PubMedCrossRefGoogle Scholar
  54. 54.
    Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255–60PubMedCrossRefGoogle Scholar
  55. 55.
    Mohanraj R, Brodie MJ. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005; 6: 382–7PubMedCrossRefGoogle Scholar
  56. 56.
    Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001; 18: 1–12CrossRefGoogle Scholar
  57. 57.
    Trevathan E, Gilliam F. Lost years: delayed referral for surgically treatable epilepsy. Neurology 2003; 61: 432–3PubMedCrossRefGoogle Scholar
  58. 58.
    Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998; 10: 171–9CrossRefGoogle Scholar
  59. 59.
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347–56PubMedCrossRefGoogle Scholar
  60. 60.
    Pellock JM, Brodie MJ. Felbamate: an update. Epilepsia 1997; 38: 1261–4PubMedCrossRefGoogle Scholar
  61. 61.
    McDonagh J. Stephen LJ, Dolan F, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 1690–4Google Scholar
  62. 62.
    Arts WFM, Geerts AT, Brouwer OF, et al. The early prognosis of epilepsy in childhood: the prediction of a poor outcome. Epilepsia 1999; 40: 726–34PubMedCrossRefGoogle Scholar
  63. 63.
    MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48: 833–41PubMedCrossRefGoogle Scholar
  64. 64.
    Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56: 1445–52PubMedCrossRefGoogle Scholar
  65. 65.
    Brodie MJ. Glasgow outcome studies. Epilepsy Res 2004; 60: 96–7Google Scholar
  66. 66.
    Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005; 46: 225–35CrossRefGoogle Scholar
  67. 67.
    Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591–602PubMedCrossRefGoogle Scholar
  68. 68.
    Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006; 6: 397–406PubMedCrossRefGoogle Scholar
  69. 69.
    Brandt C, Bethmann K, Gastens A, et al. Resistance to antiepileptic drug treatment can be counteracted by inhibition of P-glycoprotein in a rat model of temporal lobe epilepsy [abstract]. Epilepsia 2005; 46 Suppl. 6: 60Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Division of Neurology, Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales HospitalHong KongChina
  2. 2.Division of Cardiovascular and Medical Sciences, Western InfirmaryEpilepsy UnitGlasgowUK

Personalised recommendations